While diet and exercise remain cornerstones of NAFLD management, the efficacy of combined interventions, particularly GLP-1 RAs in conjunction with other therapies, has shown promise (Table 3). This evidence concerns the gene GLP1R and metabolic dysfunction-associated steatotic liver disease.